Business Description
RAPT Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75382E1091
Share Class Description:
RAPT: Ordinary SharesDescription
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.12 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -15 | |||||
| 3-Year EPS without NRI Growth Rate | -11.7 | |||||
| 3-Year FCF Growth Rate | -14.8 | |||||
| 3-Year Book Growth Rate | 0.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 29.97 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.66 | |||||
| 9-Day RSI | 40.84 | |||||
| 14-Day RSI | 40.34 | |||||
| 6-1 Month Momentum % | -49.37 | |||||
| 12-1 Month Momentum % | -86.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.9 | |||||
| Quick Ratio | 9.9 | |||||
| Cash Ratio | 9.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.6 | |||||
| Shareholder Yield % | -15.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -82.01 | |||||
| ROA % | -70.3 | |||||
| ROIC % | -699.14 | |||||
| ROC (Joel Greenblatt) % | -1651.28 | |||||
| ROCE % | -85.14 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.46 | |||||
| Price-to-Tangible-Book | 0.46 | |||||
| EV-to-EBIT | 0.42 | |||||
| EV-to-Forward-EBIT | -0.04 | |||||
| EV-to-EBITDA | 0.43 | |||||
| EV-to-Forward-EBITDA | -0.04 | |||||
| EV-to-Forward-Revenue | 242.61 | |||||
| EV-to-FCF | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 0.49 | |||||
| Price-to-Net-Cash | 0.52 | |||||
| Earnings Yield (Greenblatt) % | 238.1 | |||||
| FCF Yield % | -228.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RAPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RAPT Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.78 | ||
| Beta | 0.3 | ||
| Volatility % | 121.65 | ||
| 14-Day RSI | 40.34 | ||
| 14-Day ATR ($) | 0.239492 | ||
| 20-Day SMA ($) | 1.66025 | ||
| 12-1 Month Momentum % | -86.68 | ||
| 52-Week Range ($) | 1 - 27.35 | ||
| Shares Outstanding (Mil) | 34.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RAPT Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RAPT Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
RAPT Therapeutics Inc Frequently Asked Questions
What is RAPT Therapeutics Inc(RAPT)'s stock price today?
The current price of RAPT is $1.26. The 52 week high of RAPT is $27.35 and 52 week low is $1.00.
When is next earnings date of RAPT Therapeutics Inc(RAPT)?
The next earnings date of RAPT Therapeutics Inc(RAPT) is 2025-03-07 Est..
Does RAPT Therapeutics Inc(RAPT) pay dividends? If so, how much?
RAPT Therapeutics Inc(RAPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers